Induction of oncogene addiction shift to NF-κB by camptothecin in solid tumor cells

Biochemical and Biophysical Research Communications

Volumn 390, Issue 1, 2009, Pages 60-64

  Togano, Tomiteru ^a   Sasaki, Masataka ^a   Watanabe, Mariko ^a   Nakashima, Makoto ^a   Tsuruo, Takashi ^b   Umezawa, Kazuo ^c   Higashihara, Masaaki ^a   Watanabe, Toshiki ^d   Horie, Ryouichi ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d Graduate School of Frontier Sciences   (Japan)

Author keywords

Camptothecin; DHMEQ; NF B; Oncogene addiction; Solid tumor

Indexed keywords

CAMPTOTHECIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LUNG CANCER; ONCOGENE; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; TUMOR CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZAMIDES; CAMPTOTHECIN; CELL LINE, TUMOR; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NF-KAPPA B; ONCOGENES;

EID: 70349975702     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.066     Document Type: Article

References (27)

1. Petrelli A., and Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15 (2008) 422-432
2. Jonkers J., and Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell 6 (2004) 535-538
3. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080 (discussion 3080)
4. Huang M.E., Ye Y.C., Chen S.R., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
5. Capdeville R., Silberman S., and Dimitrijevic S. Imatinib: the first 3 years. Eur. J. Cancer 38 Suppl. 5 (2002) S77-S82
6. Gotlib J., and Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22 (2008) 1999-2010
7. Nambiar M., Kari V., and Raghavan S.C. Chromosomal translocations in cancer. Biochim. Biophys. Acta 1786 (2008) 139-152
8. Rowley J.D. Chromosome translocations: dangerous liaisons revisited. Nat. Rev. Cancer 1 (2001) 245-250
9. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
10. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
11. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
12. Ding L., Getz G., Wheeler D.A., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455 (2008) 1069-1075
13. Gilmore T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25 (2006) 6680-6684
14. Sarkar F.H., and Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front. Biosci. 13 (2008) 2950-2959
15. Cusack J.C., Liu R., and Baldwin A.S. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist. Updat. 2 (1999) 271-273
16. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5 (2005) 297-309
17. Sugimoto Y., Tsukahara S., Oh-hara T., et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50 (1990) 6925-6930
18. Watanabe M., Nakashima M., Togano T., et al. Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ. Biochem. Biophys. Res. Commun. 376 (2008) 310-314
19. Yamamoto M., Horie R., Takeiri M., et al. Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J. Med. Chem. 51 (2008) 5780-5788
20. Watanabe M., Dewan M.Z., Taira M., et al. IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab. Invest. 87 (2007) 372-382
21. Horie R., Ito K., Tatewaki M., et al. A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 88 (1996) 2422-2432
22. Wang C.Y., Cusack Jr. J.C., Liu R., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
23. Huang T.T., Wuerzberger-Davis S.M., Seufzer B.J., et al. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem. 275 (2000) 9501-9509
24. Falck J., Coates J., and Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434 (2005) 605-611
25. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
26. Li N., Banin S., Ouyang H., et al. ATM is required for IkappaB kinase (IKKk) activation in response to DNA double strand breaks. J. Biol. Chem. 276 (2001) 8898-8903
27. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., et al. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115 (2003) 565-576